DEFINITION of 'Phase 2'

The second phase of clinical trials or studies for an experimental new drug, in which the focus of the drug is on its effectiveness. Phase 2 trials typically involve hundreds of patients who have the disease or condition that the drug candidate seeks to treat. The main objective of Phase 2 trials is to obtain data on whether the drug actually works in treating a disease or indication, which is generally achieved through controlled trials that are closely monitored, while safety and side-effects also continue to be studied. Phase 2 studies also aim to establish the most effective dosage for the drug, and the optimum delivery method. Phase 2 trials usually form the biggest stumbling block in the development of a new drug.

BREAKING DOWN 'Phase 2'

Phase 2 trials are typically constructed as double blind, randomized, placebo controlled studies. This means that some of the patients enrolled in the study will receive the drug candidate, while others will receive a placebo (or a different drug). The assignment is done on a random basis and neither the participant nor the clinical investigator knows whether the participant will be receiving the drug or the placebo. This randomness and anonymity is rigorously enforced to prevent bias in the studies.

Phase 2 trials are considered successful when analysis of the data from enrolled participants reveals that the experimental drug works in treating the disease or indication. Patients who have received the experimental drug should have better clinical outcomes on a statistically significant basis than those who received the placebo (or the alternative drug). If Phase 2 trials are successful, the drug proceeds to Phase 3 studies.  

Phase 2 studies only commence if Phase 1 studies do not reveal unduly high toxicity or other safety risks of the experimental drug. While up to a third of drugs in Phase 1 studies do not progress to the Phase 2 stage because they are not safe enough, the odds of a drug progressing from Phase 2 to Phase 3 trials are even lower, about 32% to 39%.

Because of the relatively low rate of success at the Phase 2 stage, market reaction to a successful Phase 2 outcome is generally rewarded with significant stock price appreciation for the company developing the drug. The degree of stock appreciation depends on a number of factors including: the prevailing environment for equities in general and healthcare stocks in particular, the disease or indication that the drug aims to treat, the strength of the Phase 2 results, and price movement in the stock prior to the release of Phase 2 results.

RELATED TERMS
  1. Phase 1

    Phase 1 clinical studies or clinical trials are focused on the ...
  2. Clinical Trials

    A study of human volunteers that evaluates the safety and efficacy ...
  3. New Drug

    A new medication or therapy that has not been used before in ...
  4. Drug

    A substance that cures, treats, prevents or reduces the symptoms ...
  5. Abbreviated New Drug Application ...

    A written request to the U.S. Food and Drug Administration to ...
  6. Food And Drug Administration - ...

    A government agency established in 1906 with the passage of the ...
Related Articles
  1. Insights

    8 Stages Of New Drug Development

    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these trials and applications often create double-digit moves in the price ...
  2. Insights

    How Pharmaceutical Companies Price Their Drugs

    Learn more about how pharmaceutical companies price drugs, why prices are often very high and why it can be difficult to settle on a suitable price.
  3. Investing

    Corbus Gets FDA Green Light for Phase 3 Drug Study

    Corbus stock spiked after it announced that the FDA approved an upcoming Phase 3 drug study.
  4. Investing

    Pharma Balks at German Price Control (BAYRY, RHHBY)

    Drug makers are worried about a proposed new German law that would tighten price controls on prescription drugs.
  5. Investing

    Can-Fite Submits Protocol for NAFLD/NASH CF102 Drug (CANF)

    Targeting an estimated $35 billion market by 2025, Can-Fite submits a clinical trial protocol for its Phase II study of the drug
  6. Investing

    Foamix Acne Drug Fails Late-Stage Study

    Foamix Pharmaceuticals stock hit a 52-week low on failure of FMX101 drug a Phase 3 study.
  7. Investing

    GW Pharmaceuticals Cannabis Drug Aids Brain Cancer

    GW Pharma’s cannabis-derived drug combo helped treat aggressive brain cancer in a small study.
  8. Investing

    Senator Orders Investigation of Orphan Drug Abuse

    Iowa Senator Grassley ordered an inquiry into possible abuse of the Orphan Drug Act by drug makers.
  9. Investing

    Drug Giants May Benefit From China Drug Inclusion

    Pharma giants may see higher sales as the Chinese government subsidizes expensive prescription drugs.
  10. Investing

    Vertex Begins Two Cystic Fibrosis Studies (VRTX)

    Vertex Pharmaceuticals launched two Phase 2 studies to test a new class of cystic fibrosis drugs.
RELATED FAQS
  1. What are the primary risks associated with investing in the drugs sector?

    Learn more about the primary risks facing investors in the pharmaceutical and biotechnology industries. Find out how regulation ... Read Answer >>
  2. What happens during the consolidation phase of an investor's life cycle?

    Unlike the accumulation phase – where emphasis is placed on growing wealth – the consolidation phase is a balance between ... Read Answer >>
  3. What factors make the drug sector good for value investing?

    Discover what makes the drugs sector good for value investing. The perfect ingredient for value investors is to find undervalued ... Read Answer >>
  4. What are the three phases of a completed initial public offering (IPO) transformation ...

    While some large and successful companies are still privately-owned, many companies aspire toward becoming a publicly-owned ... Read Answer >>
  5. How does the strength of the IPO market affect the drugs sector?

    Discover how the strength of the IPO market affects the drugs sector. A strong IPO market reflects healthy risk appetites ... Read Answer >>
  6. What are the primary factors that drive share prices in the drugs sector?

    Learn about the primary factors that drive share prices in the drug sector. Creating and manufacturing drugs is a complex ... Read Answer >>
Hot Definitions
  1. Gross Domestic Product - GDP

    GDP is the monetary value of all the finished goods and services produced within a country's borders in a specific time period, ...
  2. Debt/Equity Ratio

    The D/E ratio indicates how much debt a company is using to finance its assets relative to the value of shareholders’ equity.
  3. Exchange-Traded Fund (ETF)

    A security that tracks an index, a commodity or a basket of assets like an index fund, but trades like a stock on an exchange.
  4. Net Present Value - NPV

    Net Present Value (NPV) is the difference between the present value of cash inflows and the present value of cash outflows ...
  5. Return On Equity - ROE

    The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability ...
  6. Bond

    A bond is a fixed income investment in which an investor loans money to an entity (corporate or governmental) that borrows ...
Trading Center